Fund moves
10.0%Stake
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BLRX · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
$0.9639−0.0961 (−9.07%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Biolinerx (BLRX) · oqro.io/stocks/BLRX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
None of the 31 ETFs OQRO follows reported BLRX in its latest N-PORT report.
Source: each ETF’s latest SEC Form N-PORT report. Vanguard ETFs are share classes of larger funds, so their figures are the whole fund’s.
No fund reported this stock
No mutual fund or ETF listed it in its latest public N-PORT report. Funds report each quarter, about two months after the quarter ends.
Institutions reporting a stake, Q2 2026
13
+1 vs Q1 2026
Share of stock reported
0.0%
67K of 2.61B shares outstanding
Change vs Q1 2026
+47K shares
4 new positions, 3 positions closed
Reported in 13F filings, which cover managers over $100M and include double counting. A 13F shows holdings on the last day of the quarter, not when shares were bought or sold. Change counts the 13 managers that reported both quarters.
Source: SEC Form 13F data sets, every filer, common stock only (options and bonds left out); 0 managers also reported puts and 1 manager calls. Amendments are applied; lines whose value was filed in thousands are scaled, and lines whose shares and value disagree are left out.